Works by Wainberg, Zev A

Results: 66
    1
    2

    A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.

    Published in:
    2017
    By:
    • Wainberg, Zev;
    • Alsina, Maria;
    • Soares, Heloisa;
    • Braña, Irene;
    • Britten, Carolyn;
    • Conte, Gianluca;
    • Ezeh, Patrick;
    • Houk, Brett;
    • Kern, Kenneth;
    • Leong, Stephen;
    • Pathan, Nuzhat;
    • Pierce, Kristen;
    • Siu, Lillian;
    • Vermette, Jennifer;
    • Tabernero, Josep;
    • Wainberg, Zev A;
    • Soares, Heloisa P;
    • Braña, Irene;
    • Britten, Carolyn D;
    • Del Conte, Gianluca
    Publication type:
    journal article
    3
    4
    5
    6

    Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.

    Published in:
    Cancers, 2024, v. 16, n. 7, p. 1323, doi. 10.3390/cancers16071323
    By:
    • Gardner, Faithlore P.;
    • Wainberg, Zev A.;
    • Fountzilas, Christos;
    • Bahary, Nathan;
    • Womack, Mark S.;
    • Macarulla, Teresa;
    • Garrido-Laguna, Ignacio;
    • Peterson, Patrick M.;
    • Borazanci, Erkut;
    • Johnson, Melissa;
    • Ceccarelli, Matteo;
    • Pelzer, Uwe
    Publication type:
    Article
    7

    Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    Correction Notice
    8

    A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

    Published in:
    2023
    By:
    • Curigliano, Giuseppe;
    • Shapiro, Geoffrey I.;
    • Kristeleit, Rebecca S.;
    • Abdul Razak, Albiruni R.;
    • Leong, Stephen;
    • Alsina, Maria;
    • Giordano, Antonio;
    • Gelmon, Karen A.;
    • Stringer-Reasor, Erica;
    • Vaishampayan, Ulka N.;
    • Middleton, Mark;
    • Olszanski, Anthony J.;
    • Rugo, Hope S.;
    • Kern, Kenneth A.;
    • Pathan, Nuzhat;
    • Perea, Rachelle;
    • Pierce, Kristen J.;
    • Mutka, Sarah C.;
    • Wainberg, Zev A.
    Publication type:
    journal article
    9

    Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.

    Published in:
    British Journal of Cancer, 2019, v. 121, n. 4, p. 318, doi. 10.1038/s41416-019-0517-3
    By:
    • Veitch, Zachary W.;
    • Cescon, David W.;
    • Denny, Trisha;
    • Yonemoto, Lisa-Maria;
    • Fletcher, Graham;
    • Brokx, Richard;
    • Sampson, Peter;
    • Li, Sze-Wan;
    • Pugh, Trevor J.;
    • Bruce, Jeffrey;
    • Bray, Mark R.;
    • Slamon, Dennis J.;
    • Mak, Tak W.;
    • Wainberg, Zev A.;
    • Bedard, Philippe L.
    Publication type:
    Article
    10
    11
    12
    13
    14

    Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103).

    Published in:
    Journal of Clinical Pharmacology, 2024, v. 64, n. 5, p. 544, doi. 10.1002/jcph.2397
    By:
    • Garralda, Elena;
    • Oh, Do Youn;
    • Italiano, Antoine;
    • Bedard, Philippe L.;
    • Delord, Jean‐Pierre;
    • Calvo, Emiliano;
    • LoRusso, Patricia;
    • Wainberg, Zev;
    • Cervantes, Andres;
    • Rodriguez‐Vida, Alejo;
    • Shemesh, Colby S.;
    • Sane, Rucha;
    • Mendus, Diana;
    • Ding, Hao;
    • Hendricks, Robert;
    • Meng, Ray;
    • Cho, Byoung Chul;
    • Kim, Tae Won;
    • Wu, Benjamin
    Publication type:
    Article
    15
    16

    Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.

    Published in:
    2021
    By:
    • Gelderblom, Hans;
    • Wagner, Andrew J.;
    • Tap, William D.;
    • Palmerini, Emanuela;
    • Wainberg, Zev A.;
    • Desai, Jayesh;
    • Healey, John H.;
    • Sande, Michiel A. J.;
    • Bernthal, Nicholas M.;
    • Staals, Eric L.;
    • Peterfy, Charles G.;
    • Frezza, Anna Maria;
    • Hsu, Henry H.;
    • Wang, Qiang;
    • Shuster, Dale E.;
    • Stacchiotti, Silvia;
    • van de Sande, Michiel A J
    Publication type:
    journal article
    17
    18
    19
    20
    21
    22

    Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

    Published in:
    Gastric Cancer, 2024, v. 27, n. 3, p. 558, doi. 10.1007/s10120-024-01466-w
    By:
    • Wainberg, Zev A.;
    • Kang, Yoon-Koo;
    • Lee, Keun-Wook;
    • Qin, Shukui;
    • Yamaguchi, Kensei;
    • Kim, In-Ho;
    • Saeed, Anwaar;
    • Oh, Sang Cheul;
    • Li, Jin;
    • Turk, Haci Mehmet;
    • Teixeira, Alexandra;
    • Hitre, Erika;
    • Udrea, Adrian A.;
    • Cardellino, Giovanni Gerardo;
    • Sanchez, Raquel Guardeño;
    • Zahlten-Kümeli, Anita;
    • Taylor, Kate;
    • Enzinger, Peter C.
    Publication type:
    Article
    23
    24

    Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.

    Published in:
    Gastric Cancer, 2021, v. 24, n. 6, p. 1330, doi. 10.1007/s10120-021-01200-w
    By:
    • Van Cutsem, Eric;
    • Amonkar, Mayur;
    • Fuchs, Charles S.;
    • Alsina, Maria;
    • Özgüroğlu, Mustafa;
    • Bang, Yung-Jue;
    • Chung, Hyun Cheol;
    • Muro, Kei;
    • Goekkurt, Eray;
    • Benson III, Al B.;
    • Sun, Weijing;
    • Wainberg, Zev A.;
    • Norquist, Josephine M.;
    • Chen, Xinqun;
    • Shih, Chie-Schin;
    • Shitara, Kohei
    Publication type:
    Article
    25

    Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

    Published in:
    Gastric Cancer, 2019, v. 22, n. 4, p. 828, doi. 10.1007/s10120-018-00909-5
    By:
    • Bang, Yung-Jue;
    • Kang, Yoon-Koo;
    • Catenacci, Daniel V.;
    • Muro, Kei;
    • Fuchs, Charles S.;
    • Geva, Ravit;
    • Hara, Hiroki;
    • Golan, Talia;
    • Garrido, Marcelo;
    • Jalal, Shadia I.;
    • Borg, Christophe;
    • Doi, Toshihiko;
    • Yoon, Harry H.;
    • Savage, Mary J.;
    • Wang, Jiangdian;
    • Dalal, Rita P.;
    • Shah, Sukrut;
    • Wainberg, Zev A.;
    • Chung, Hyun Cheol
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32

    Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial.

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2015, v. 22, n. 2, p. 535, doi. 10.1245/s10434-014-4013-y
    By:
    • Bilchik, Anton;
    • Wainberg, Zev;
    • Nissan, Aviram;
    • Slamon, Dennis;
    • Protic, Mladjan;
    • Avital, Itzhak;
    • Chen, Hsiao-Wang;
    • Chen, David;
    • Sim, Myung;
    • Elashoff, David;
    • Stojadinovic, Alexander
    Publication type:
    Article
    33
    34
    35
    36
    37

    Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study.

    Published in:
    Clinical Colorectal Cancer, 2013, v. 12, n. 4, p. 239, doi. 10.1016/j.clcc.2013.09.001
    By:
    • Bendell, Johanna C.;
    • Tourmgand, Christophe;
    • Swieboda-Sadlej, Anna;
    • Barone, Carlo;
    • Wainberg, Zev A.;
    • Jong Gwang Kim;
    • Pencay, Carles;
    • Pastorelli, Davide;
    • Tarazi, Jamal;
    • Rosbrook, Brad;
    • Bloom, Joanna;
    • Ricart, Alejandro D.;
    • Kim, Sinil;
    • Sobrero, Alberto F.
    Publication type:
    Article
    38
    39
    40
    41
    42
    43
    44

    Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.

    Published in:
    PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0054014
    By:
    • Shah, Manish A.;
    • Wainberg, Zev A.;
    • Catenacci, Daniel V. T.;
    • Hochster, Howard S.;
    • Ford, James;
    • Kunz, Pamela;
    • Lee, Fa-Chyi;
    • Kallender, Howard;
    • Cecchi, Fabiola;
    • Rabe, Daniel C.;
    • Keer, Harold;
    • Martin, Anne-Marie;
    • Liu, Yuan;
    • Gagnon, Robert;
    • Bonate, Peter;
    • Liu, Li;
    • Gilmer, Tona;
    • Bottaro, Donald P.
    Publication type:
    Article
    45
    46
    47
    48
    49
    50